The Enhanced Games is moving beyond competition and into peptides

The Enhanced Games is a Las Vegas-based sporting competition launching this May where performance-enhancing drugs are not just permitted but central to the concept. Now the company behind it has launched a consumer health platform called Live Enhanced, with peptides at the center, timed almost perfectly to a regulatory window that could make injectable compounds widely available for the first time.

Here’s what’s being offered

Live Enhanced sells supplements and prescription protocols including hormone replacement therapy for men and women, longevity compounds, and peptides. At launch, the company offers Sermorelin, a peptide that stimulates growth hormone release, with Tesamorelin, Glutathione, and Oxytocin coming next.Those are all currently legal to compound in the US.

A second tier of eight additional peptides — including CJC-1295, Ipamorelin, Thymosin Alpha-1, TB-500, GHRP-2/6, Kisspeptin-10, Semax, and Selank — is contingent on regulatory approval. That second list is where it gets complicated.

The GLP-1 boom put peptides on the mainstream radar. While several have earned their reputation through large-scale clinical trials, most of the performance and longevity peptides gaining consumer attention now have significantly thinner evidence behind them.

Why now

For years, many of these compounds lived in a grey market: not approved for consumer use, not quite illegal, or sold openly online under “for research purposes only” disclaimers. The FDA formally restricted a set of them, flagging several as posing potentially significant safety risks.

In February, Health Secretary Robert F. Kennedy Jr. said on Joe Rogan’s podcast that the FDA would work to move approximately 14 restricted peptide compounds (though he didn’t specify which ones) from the restricted Category 2 list to Category 1, which would allow licensed 503A pharmacies to compound and dispense them again. Enhanced is positioning itself to have product ready the moment those approvals land.

Enhanced is positioning itself to be among the first consumer health platforms ready to sell those compounds the moment regulatory doors open.

What to watch

The regulatory picture here is still moving. Kennedy’s podcast comments signaled intent, not policy, and the FDA has not announced formal rulemaking on peptide reclassification. Enhanced’s full catalog is contingent on those approvals landing. Either way, whether you’re considering Enhanced or any other platform entering this space, a physician who knows your history is a better starting point than a podcast.

If deregulation moves forward, Enhanced won’t be alone for long. The consumer peptide market has been watching this regulatory moment build for months, and this platform is almost certainly the first of several.